Amneal's Parkinson's pill approved, Novo Nordisk withdraws Wegovy approval expansion bid, FDA delays BeiGene Tevimbra decision [The good, the bad, the ugly]

Off Script: A Pharma Manufacturing Podcast

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly.

Up this week:

The good — Amneal gets FDA nod for Parkinson’s pill

The bad — Novo Nordisk withdraws bid for Wegovy label expansion in heart failure

The ugly — FDA delays decision on BeiGene Tevimbra as a first-line therapy